{
    "clinical_study": {
        "@rank": "87621", 
        "brief_summary": {
            "textblock": "The purpose of this trial is to determine the safety of hMN14 at different dose levels in\n      the treatment of either colorectal or breast cancer."
        }, 
        "brief_title": "Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer", 
        "completion_date": "June 2003", 
        "condition": [
            "Colorectal Cancer", 
            "Colon Cancer", 
            "Rectal Cancer", 
            "Colorectal Neoplasms", 
            "Colorectal Carcinoma", 
            "Breast Cancer", 
            "Breast Neoplasms"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Neoplasms", 
                "Carcinoma", 
                "Colonic Neoplasms", 
                "Rectal Neoplasms", 
                "Colorectal Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Disease Characteristics:\n\n          -  Histologic or cytologic diagnosis or either, colonic, rectal, or breast carcinoma\n\n          -  Measurable lesion diagnosed by CT scan\n\n          -  Recurrent/metastatic disease considered surgically unresectable.\n\n        Prior/Concurrent Therapy:\n\n          -  Chemotherapy: Patients who either have failed at least one regimen of standard\n             systemic therapy, or are clinically asymptomatic and are not presently being\n             considered for chemotherapy (Enrollment must occur at least 4 weeks beyond last\n             treatment)\n\n          -  Other: Prior treatment with investigational agents is excluded unless follow-up is\n             completed and patient is off study\n\n        Patient Characteristics/Inclusion Criteria:\n\n          -  Performance Status: Patients with a Karnofsky performance status > 70% (or\n             equivalent, ECOG 0-1) and expected survival of at least 3 months.\n\n          -  Hematopoietic: WBC >/= 3000 mm3, neutrophils >/= 1500 mm3, platelets >/= 75,000, CEA\n             < 300 ng/mL\n\n          -  Hepatic: Serum bilirubin </= 2.0 mg/dL, ALT < 2.5 x IULN\n\n          -  Cardiovascular: Patients with LVEF >/= 40% by required MUGA/2D-ECHO study.\n\n          -  Pulmonary: Patients with FEV1 >/= 60% by required Pulmonary Function Tests\n\n          -  Other: Patients agreeing to use a medically effective method of contraception during\n             and for a period of 3 months after the treatment period.  A pregnancy test will be\n             preformed on each premenopausal female of childbearing potential immediately prior to\n             entry into the study.  Patients able to understand and give written informed consent.\n              Patients with a significant concurrent medical condition that could affect the\n             patient's ability to tolerate or complete the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "30", 
        "firstreceived_date": "July 11, 2002", 
        "id_info": {
            "nct_id": "NCT00041652", 
            "org_study_id": "IM-T-hMN14-04"
        }, 
        "intervention": {
            "intervention_name": "hMN14 (labetuzumab)", 
            "intervention_type": "Drug"
        }, 
        "keyword": [
            "Colorectal Cancer", 
            "Colon Cancer", 
            "Rectal Cancer", 
            "Colorectal Neoplasms", 
            "Colorectal Carcinoma", 
            "Breast Cancer", 
            "Breast Neoplasms"
        ], 
        "lastchanged_date": "October 21, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Newport Beach", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "92658"
                }, 
                "name": "Hoag Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase I/II Clinical Trial of Immunotherapy With Humanized MN-14 IgG in Recurrent, Metastatic, Unresectable Colorectal and Breast Carcinomas", 
        "overall_official": [
            {
                "affiliation": "Immunomedics, Inc.", 
                "last_name": "Terence Rugg, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Immunomedics, Inc.", 
                "last_name": "Lauri Welles, MD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1/Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00041652"
        }, 
        "source": "Immunomedics, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Immunomedics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2000", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2005"
    }, 
    "geocoordinates": {
        "Hoag Cancer Center": "33.619 -117.929"
    }
}